StockNews.com began coverage on shares of InspireMD (NYSE:NSPR - Free Report) in a report published on Tuesday morning. The brokerage issued a sell rating on the stock.
Separately, Lake Street Capital assumed coverage on shares of InspireMD in a research report on Wednesday, December 11th. They issued a "buy" rating and a $5.00 price target on the stock.
View Our Latest Stock Analysis on InspireMD
InspireMD Stock Performance
Shares of NYSE:NSPR traded up $0.01 during mid-day trading on Tuesday, reaching $2.76. 17,256 shares of the company's stock were exchanged, compared to its average volume of 35,996. InspireMD has a twelve month low of $1.81 and a twelve month high of $3.80. The firm has a market capitalization of $81.80 million, a price-to-earnings ratio of -3.67 and a beta of 0.88. The business's fifty day moving average price is $2.86 and its 200-day moving average price is $2.76.
Hedge Funds Weigh In On InspireMD
A number of institutional investors have recently modified their holdings of the company. Affiance Financial LLC increased its stake in InspireMD by 2.9% during the 4th quarter. Affiance Financial LLC now owns 189,122 shares of the company's stock valued at $497,000 after purchasing an additional 5,376 shares in the last quarter. Renaissance Technologies LLC bought a new stake in shares of InspireMD during the fourth quarter worth about $27,000. Legato Capital Management LLC acquired a new stake in shares of InspireMD in the 4th quarter worth about $47,000. Schonfeld Strategic Advisors LLC lifted its position in InspireMD by 153.2% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company's stock valued at $79,000 after acquiring an additional 18,233 shares in the last quarter. Finally, Northern Trust Corp lifted its position in InspireMD by 103.7% in the 4th quarter. Northern Trust Corp now owns 48,022 shares of the company's stock valued at $126,000 after acquiring an additional 24,452 shares in the last quarter. 44.78% of the stock is owned by institutional investors and hedge funds.
About InspireMD
(
Get Free Report)
InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.
Featured Articles
Before you consider InspireMD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InspireMD wasn't on the list.
While InspireMD currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
